Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 109,522,504
  • Shares Outstanding, K 2,550,000
  • Annual Sales, $ 16,611 M
  • Annual Income, $ 5,636 M
  • 36-Month Beta 0.63
  • Price/Sales 6.95
  • Price/Cash Flow 18.67
  • Price/Book 19.22

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.67 +3.07%
on 07/07/17
44.56 -3.61%
on 06/26/17
-0.76 (-1.74%)
since 06/21/17
3-Month
36.39 +18.03%
on 04/24/17
44.56 -3.61%
on 06/26/17
+7.07 (+19.70%)
since 04/21/17
52-Week
30.89 +39.04%
on 11/23/16
57.41 -25.19%
on 08/01/16
-12.07 (-21.94%)
since 07/21/16

Most Recent Stories

More News
AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

NVO : 42.95 (-1.38%)
JNJ : 135.31 (-0.92%)
ABBV : 74.63 (+0.84%)
PFE : 33.48 (-0.18%)
Can Merck (MRK) Pull Off a Surprise this Earnings Season?

Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition....

NVO : 42.95 (-1.38%)
MRK : 62.63 (-0.49%)
VRTX : 163.17 (+2.41%)
PFE : 33.48 (-0.18%)
Is Novo Nordisk (NVO) Stock a Solid Choice Right Now?

Novo Nordisk (NVO) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.

NVO : 42.95 (-1.38%)
What Lies in Store for Glaxo (GSK) this Earnings Season?

The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.

MYL : 39.17 (-0.81%)
NVO : 42.95 (-1.38%)
PFE : 33.48 (-0.18%)
GSK : 42.66 (-0.26%)
Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?

Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

NVO : 42.95 (-1.38%)
LLY : 84.66 (-0.11%)
PFE : 33.48 (-0.18%)
SNY : 47.71 (-0.73%)
Novo Nordisk reports on share repurchase programme

Global healthcare company Novo Nordisk A/S (CPH:NOVOB) reported on a Monday that under its share repurchase programme, as of 17 July 2017, it has repurchased a total of 28,085,479 B shares equal to a transaction...

NVO : 42.95 (-1.38%)
Novo Nordisk reports on share repurchase programme

Global healthcare company Novo Nordisk A/S (CPH:NOVOB) reported on a Monday that under its share repurchase programme, as of 17 July 2017, it has repurchased a total of 28,085,479 B shares equal to a transaction...

NVO : 42.95 (-1.38%)
Novo Nordisk reports on share repurchase programme

Global healthcare company Novo Nordisk A/S (CPH:NOVOB) reported on a Monday that under its share repurchase programme, as of 17 July 2017, it has repurchased a total of 28,085,479 B shares equal to a transaction...

NVO : 42.95 (-1.38%)
Why Did Radius Health (RDUS) Stock Plummet Today?

Shares of Radius Health (RDUS) dropped more than 7.8% in early morning trading hours Monday after the company announced that Jesper Hoiland, a former top-ranking executive at Novo Nordisk (NVO), has been...

NVO : 42.95 (-1.38%)
RDUS : 42.22 (-0.28%)
LLY : 84.66 (-0.11%)
AMGN : 180.21 (+0.50%)
Novo Nordisk reports on share repurchase programme

Global healthcare company Novo Nordisk A/S (CPH:NOVOB) reported on Tuesday that under its share repurchase programme, it has accumulated 27,125,479 B shares equal to a transaction value of DKK6,994,402,115....

NVO : 42.95 (-1.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Support & Resistance

2nd Resistance Point 43.41
1st Resistance Point 43.18
Last Price 42.95
1st Support Level 42.61
2nd Support Level 42.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.